Baird raised the firm’s price target on Axsome Therapeutics to $112 from $108 and keeps an Outperform rating on the shares. The firm said they are encouraged that 1Q24 net product revenue grew over 4Q23, despite a couple of weeks of impact from the Change Healthcare cyberattack, on top of the usual negative seasonality impact.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on AXSM:
- Axsome Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update
- AXSM Earnings this Week: How Will it Perform?
- Axsome Therapeutics recognizes May as Mental Health Awareness Month
- Axsome Therapeutics Recognizes May as Mental Health Awareness Month
- Axsome Therapeutics upgraded to Overweight from Equal Weight at Morgan Stanley